Sample Size Based on Pharmacodynamic endpoints [Power / Sample Size]

posted by sury – India, 2019-04-05 06:36 (925 d 16:50 ago) – Posting: # 20122
Views: 2,847

Thanks for your reply.....but i have few more doubts on this

Can we use the pharmacokinetic parameter ISCV for the sample size estimation for the clinical endpoint bioequivalence study?
is it will be in accordance with the regulatory requirement?


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5[Helmut]

Complete thread:

Activity
 Admin contact
21,729 posts in 4,543 threads, 1,543 registered users;
online 13 (0 registered, 13 guests [including 3 identified bots]).
Forum time: Saturday 23:27 CEST (Europe/Vienna)

If you want to converse with me,
define your terms.    Voltaire

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5